Nephros heads into its fiscal third-quarter report with a credibility question rather than a growth question. Last quarter delivered record revenue, record profit and the most upbeat tone management has struck in some time. A meaningful slice of that showing, however, came from a one-time tariff refund. The stock has since given back its post-earnings enthusiasm. This report is the first clean look at what the business earns once the accounting tailwind is gone.
Wall Street is not asking for heroics. Consensus calls for earnings of $0.02 per share on revenue of about $5.3 million. That revenue figure would be up roughly 11% from the $4.8 million posted a year ago, a respectable if unspectacular pace. It would also be a step down from the $6.0 million record set in the June quarter. Earnings are expected to slip about a third from last year's $0.03 and fall sharply from the prior quarter's $0.06. Management does not issue numeric guidance, so the Street's model rests on its own read of how much of last quarter's strength was durable. The sequential revenue decline built into estimates suggests analysts treated at least part of the June surge as lumpy.
The margin line is where the story gets tested. Reported gross margin jumped to 67% last quarter, but roughly 9 points came from a $600,000 tariff refund. Only about $100,000 of that refund related to the quarter's own sales. Strip it out and margins look much closer to the 57% to 58% range of the prior two quarters. Management also flagged three ongoing pressures: a residual 10% tariff, a stronger euro raising product and shipping costs, and a growing mix of lower-margin service and commercial work. A gross margin that holds near the high 50s would confirm that the underlying business is stable. A slide into the mid-50s would suggest the mix shift and currency drag are eating into the economics faster than volume growth can offset.
On the top line, the encouraging part of last quarter was its breadth. Growth came from core programmatic customers and a near tripling of service revenue rather than from emergency outbreak orders, which tend to fade. Active sites climbed to about 1,724, and management said revenue per site was rising. The newly matured Filter Tracker app is meant to automate replacement reminders and lock in recurring filter sales. Continued gains in site count and steady programmatic revenue would validate the recurring-revenue thesis. Early contributions from the Greater New York and Puerto Rico expansion, where Legionnaires concerns have driven inbound inquiries, would add support. Investors should not expect much yet from the new PFAS and microplastics products, which management placed two to three quarters out.
Cash flow deserves equal attention. Operating cash flow swung to a $990,000 use in the first half as receivables and inventory built up. Cash stood at $4.7 million at the end of June. For a company this size, evidence that those receivables are converting to cash would matter as much as the income statement.
The market has turned skeptical. Sentiment has moved from 38.9% bearish before the last report to 71.8% bearish now. The shares are down 14% since the prior release while the S&P 500 was essentially flat. At $3.27, the stock sits below its 200-day moving average of $3.68. It is near the bottom of a post-earnings range that stretched from $3.01 to $4.87. That pessimism lowers the bar somewhat, but it also reflects real doubt about the quality of last quarter's beat. The central issue is whether Nephros can show underlying margins holding near prior levels while site growth and service revenue keep compounding. If it can, the record quarter looks like a turning point. If not, it looks like a refund-flattered peak.